Abbott Labs (ABT) Offering Possible 21.65% Return Over the Next 5 Calendar Days

Abbott Labs's most recent trend suggests a bearish bias. One trading opportunity on Abbott Labs is a Bear Call Spread using a strike $79.50 short call and a strike $84.50 long call offers a potential 21.65% return on risk over the next 5 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $79.50 by expiration. The full premium credit of $0.89 would be kept by the premium seller. The risk of $4.11 would be incurred if the stock rose above the $84.50 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Abbott Labs is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Abbott Labs is bearish.

The RSI indicator is at 54.82 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Abbott Labs

Abbott and the Abbott Fund Support Relief Efforts for Cyclone Idai
Thu, 11 Apr 2019 19:16:00 +0000
ABBOTT PARK, Ill., April 11, 2019 /PRNewswire/ — Abbott (ABT) and its foundation, the Abbott Fund, are providing more than $500,000 in grants and healthcare products to support relief efforts for Cyclone Idai in Southeast Africa, including Mozambique, Malawi and Zimbabwe. According to the United Nations, significant aid is needed to help meet immediate needs across the region, following the devastating impact of Cyclone Idai and continued heavy rains and flooding. This includes focused efforts in Mozambique to address cholera, malaria and other diseases, as well as to meet immediate needs for food, water, shelter and medical care across the region.

Abbott (ABT) Earnings Expected to Grow: Should You Buy?
Wed, 10 Apr 2019 14:30:02 +0000
Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Abbott (ABT) Gains As Market Dips: What You Should Know
Tue, 09 Apr 2019 21:50:09 +0000
Abbott (ABT) closed at $78.67 in the latest trading session, marking a +0.19% move from the prior day.

The Abbott Laboratories (NYSE:ABT) Share Price Is Up 113% And Shareholders Are Boasting About It
Sat, 06 Apr 2019 14:01:30 +0000
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put i…

AbbVie: High-Yield Dividend Aristocrat Offering a No-Fee DRIP
Fri, 05 Apr 2019 21:08:26 +0000
Dividend growth investing has proven to be one of the best ways for retail investors to accumulate wealth over the long term. One of the factors that boosts the wealth-creating power of dividend growth investing, is dividend reinvestment. Dividend reinvesting makes one's share count rise, even if there is no additional principal invested into new shares.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.